查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138391

顯微鏡下多血管炎 (MPA) 治療的全球市場 - 2022-2029

Global Microscopic Polyangiitis (MPA) Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球顯微多血管炎 (MPA) 治療市場的增長是由慢性病患病率上升和人口老齡化、細胞分離技術進步、對生物製藥的需求增加推動的，幹細胞研究是由某些因素驅動的，例如增加在市場增長的一些主要驅動力是：

微型多血管炎 (MPA) 新療法的不斷發展和強大的管道藥物預計將在預測期內推動全球微型多血管炎 (MPA) 治療市場。

治療顯微鏡下多血管炎的在研藥物包括阿巴西普和 IFX 1。 2018年7月，德國臨床階段生物製藥公司InflaRx N.V.向美國食品藥品監督管理局宣布，將開展IFX-1治療抗中性粒細胞胞漿自身抗體（ANCA）血管炎的2期臨床試驗。（FDA） ) 清除，ANCA 的存在表明患者患有微血管炎 (MPA)。 IFX-1是補體系統的抑製劑，可以中和C5a成分而不影響正常的免疫功能。因此，預計在預測期內增加用於開發 MPA 新療法的臨床試驗將促進微觀多血管炎市場的增長。

美國食品藥品監督管理局 (FDA)、歐洲藥品管理局 (EMA) 和藥品和保健品監管機構 (MHRA) 等監管機構越來越多地批准用於治療 MPA 的多種藥物將推動市場增長。我正在進一步推動。例如，2018 年 10 月，Genentech 患有肉芽腫性多血管炎和顯微鏡下多血管炎 (MPA)，通過糖皮質激素和環磷□胺的誘導治療得到改善。獲得美國食品和藥物管理局 (FDA) 批准更新 Rituxan 的標籤以包括後續治療成人患者的信息。

阻礙顯微鏡下多血管炎 (MPA) 治療市場增長的藥物相關副作用

然而，全球微觀多血管炎市場的增長受到多種因素的阻礙，包括藥物引起的副作用。腎上腺皮質激素引起的副作用包括皮膚變薄和劇烈疼痛。單克隆抗體的生產需要昂貴且耗時的研究。硫唑嘌呤與副作用有關，例如腹瀉、關節疼痛、失去協調、癲癇發作和視力改變。

行業分析

全球微觀多血管炎（MPA）治療市場基於波特五力分析、供應鏈分析、監管分析、定價分析、專利分析、流行病學和未滿足需求等多種行業因素，提供了深入的市場分析。

全球顯微多血管炎 (MPA) 治療市場報告提供了大約 40 多個市場數據表、45 多個圖表和 180 頁的結構。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 驅動程序
    • 增加研發投入
    • 在研藥物增加
  • 限制因素
    • 藥物的副作用
  • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求

第六章藥物

  • 利妥昔單抗（利妥昔單抗）
  • 環磷□胺（環磷□胺）
  • 硫唑嘌呤
  • 潑尼松
  • 阿巴科麵包
  • 其他

第 7 章給藥途徑

  • 口語
  • 注入

第 8 章按分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • Celltrion Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • ChemoCentryx Inc.
  • Teijin Pharma Ltd.
  • Sandoz International GmbH
  • Genentech, Inc.
  • InflaRx N.V.
  • Bristol-Myers Squibb Company
  • Amerigen Pharmaceuticals Limited
  • TTY Biopharm Company Ltd.

第12章 DataM

簡介目錄
Product Code: DMPH2601

Market Overview

Microscopic Polyangiitis (MPA) Treatment Market size was valued at US$ XX billion in 2021 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 5.5% during the forecast period (2022-2029).

Microscopic polyangiitis (MPA), known as ANCA-associated vasculitis, is a rare disorder characterized by inflammation of the blood vessels that restricts the blood flow and damage vital organs and tissues. Some other forms of ANCA-associated vasculitis include eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA). MPA mostly affects the small to medium-sized blood vessels, particularly involving the kidneys, lungs, nerves, skin, and joints. It can worsen rapidly, so early diagnosis and treatment are essential to prevent kidney or respiratory damage or organ failure.

Microscopic polyangiitis can affect both men and women of all ages, but the average age is around 50, and men may get MPA more often. MPA is rare, with prevalence at 1 to 3 cases per 100,000 people in the United States. The incidence is around 2 cases per 100,000 people in the United Kingdom and an estimated 1 case per 100,000 people in Sweden.

MPA is diagnosed by several tests including, the blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for diagnosis of red blood cells (RBCs), and imaging procedures such as computed tomography (CT), magnetic resonance (MR) scan, and X-rays. If these tests are positive for the presence of MPA, biopsy (tissue sample testing) is performed to confirm the presence of MPA.

Market Dynamics

The global microscopic polyangiitis (MPA) treatment market growth driven by certain factors such as rising prevalence of chronic diseases with growing geriatric population, technological advancement in cell isolation, increasing demand for biopharmaceuticals, and increasing stem cell research. are among the key factors driving the market growth.

Rising development of new treatments for MPA and robust pipeline drugs, is expected to drive the global microscopic polyangiitis (MPA) treatment market during the forecast period

Some of the pipeline drugs for treating microscopic polyangiitis are Abatacept, IFX 1, among others. In July 2018, InflaRx N.V., a German clinical-stage bio-pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for conducting phase II clinical trials of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of ANCA indicates that the patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes the C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatments for MPA is expected to boost the microscopic polyangiitis market's growth over the forecast period.

The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), among others for several drugs for the treatment of MPA, is further driving the growth of the market. For instance, in October 2018, Genentech received the U.S. Food and Drug Administration (FDA) approval to update the Rituxan label to include the follow-up treatment information of adult patients suffering from granulomatosis with polyangiitis and microscopic polyangiitis (MPA), who had shown improvement in medical condition with the glucocorticoid and cyclophosphamide induction treatment.

Side-effects associated with the drugs hampering the growth of the microscopic polyangiitis (MPA) treatment market

However, the global microscopic polyangiitis market growth is hindered by some factors, including side-effects caused by the drugs. Some of the side-effects caused by corticosteroids include skin thinning and intense pain. Monoclonal antibody production involves costly and time-consuming research. Azathioprine involves side effects such as diarrhea, joint pain, loss of coordination, seizure, and vision changes.

Industry Analysis

The global microscopic polyangiitis (MPA) treatment market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis, patent analysis, epidemiology, unmet needs.

Segment Analysis

The drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The treatment of microscopic polyangiitis is based on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids such as prednisone combined with other medications that suppress the immune system and reduce inflammation. However, even with treatment, MPA is a chronic condition with periods of relapse and remission, so ongoing medical care and monitoring are necessary. Some of the drugs available for MPA treatment are Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, and others. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab to treat MPA and GPA. (Biologic medications are complex proteins derived from living organisms. They target certain parts of the immune system to control inflammation.). Rituximab is expected to gain maximum share over the forecast period (2020-2027).

On the other hand, cyclophosphamide is growing at a significant growth rate over the forecast period. It is a chemotherapy-type drug that blocks the abnormal growth of certain cells in the body in combination with prednisone. Prednisone is typically started at a high dose and then tapered off slowly. Cyclophosphamide lowers the body's ability to fight infection, hence usually limited to a three- to six-month period and replaced by less toxic medications such as mycophenolate mofetil azathioprine, or methotrexate, a drug commonly used to treat rheumatoid arthritis. Some milder forms of MPA are typically treated with a combination of prednisone and methotrexate.

Geographical Analysis

North America region holds the largest market share of the global microscopic polyangiitis (MPA) treatment market

North American region is dominating the global microscopic polyangiitis (MPA) treatment market accounting for the maximum market share in 2022 due to the increasing development of drugs to treat MPA. In the United States, the annual incidence of microscopic polyangiitis is 3.6 cases per million persons, and the prevalence is one to three cases per 100,000 population. In September 2022, Roche received the U.S. Food and Drug Administration (FDA) approval for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age and older.

Competitive Landscape

The microscopic polyangiitis (MPA) treatment market is highly competitive and consists of several major players and new players in the market. Some of the key players which are contributing to the growth of the market are ChemoCentryx Inc., Celltrion, Inc., Teijin Pharma Ltd, Sandoz International GmbH (Novartis Division), TTY Biopharm Company Ltd, Genentech, Inc., InflaRx N.V., Bristol-Myers Squibb Company, Amerigen Pharmaceuticals Limited, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, contributing to the growth of the microscopic polyangiitis (MPA) treatment market globally. For instance,

On 4th May 2020, Israeli generics giant Teva Pharmaceutical Industries and partner, South Korean biotechnology company Celltrion, launched their rituximab biosimilar Truxima (TL011) in the US. Truxima (rituximab-abbs) is now available in the US for the treatment of patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's granulomatosis), and microscopic polyangiitis.

In January 2020, Pfizer announced to introduce three new biosimilars this year. The company plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr), Rituxan biosimilar Ruxience (rituximab-pvvr), and Herceptin biosimilar Trazimera (trastuzumab-qyyp). The audience is available to treat adult patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Key Companies to Watch

Celltrion Inc

Overview: Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Jung Jin Seo, is the richest person in South Korea.

Product Portfolio: Truxima (rituximab)- Targets a specific protein in the immune system that may trigger inflammation of the blood vessels.

The global microscopic polyangiitis (MPA) treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising R&D investments
    • 4.2.2. The growing number of pipeline drugs
    • 4.2.3. XX
  • 4.3. Restraints:
    • 4.3.1. Side-effects caused by drugs
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs

6. By Drug

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 6.1.2. Market Attractiveness Index, By Drug Segment
  • 6.2. Rituximab (Rituxan)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3. Cyclophosphamide (Cytoxan)
  • 6.4. Azathioprine
  • 6.5. Prednisone
  • 6.6. Avacopan
  • 6.7. Others

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 7.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 7.2. Oral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Injectable

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 8.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 8.2. Hospital pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Retail pharmacies
  • 8.4. Online pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Celltrion Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. ChemoCentryx Inc.
  • 11.3. Teijin Pharma Ltd.
  • 11.4. Sandoz International GmbH
  • 11.5. Genentech, Inc.
  • 11.6. InflaRx N.V.
  • 11.7. Bristol-Myers Squibb Company
  • 11.8. Amerigen Pharmaceuticals Limited
  • 11.9. TTY Biopharm Company Ltd.

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us